Flow Signals: Evidence from Patent and Alliance Portfolios in the US Biopharmaceutical Industry

2017 ◽  
Vol 55 (2) ◽  
pp. 232-264 ◽  
Author(s):  
Turanay Caner ◽  
Olga Bruyaka ◽  
John E. Prescott
Keyword(s):  
Biopharmaceutical Industry ◽  
The Us ◽  
Alliance Portfolios

THE EFFECTS OF ALLIANCE PORTFOLIO DIVERSITY ON INNOVATION PERFORMANCE: A STUDY OF PARTNER AND ALLIANCE CHARACTERISTICS IN THE BIO-PHARMACEUTICAL INDUSTRY

2017 ◽  
Vol 21 (01) ◽  
pp. 1750001 ◽  
Author(s):  
KLAUS MARHOLD ◽  
MARCO JINHWAN KIM ◽  
JINA KANG
Keyword(s):  
Pharmaceutical Industry ◽  
Innovation Performance ◽  
Biopharmaceutical Industry ◽  
Negative Interaction ◽  
Alliance Portfolio ◽  
The Us ◽  
Partner Characteristics ◽  
Two Measures ◽  
Alliance Partners ◽  
Diversity Research

This study investigates the effects of alliance portfolio diversity on the innovation performance of firms. Alliance portfolio diversity is defined using partner characteristics (partner industrial background) and alliance characteristics (alliance objective). We also investigate the interaction between these two measures of diversity on innovation performance. The hypotheses are tested on a dataset of R&D alliances in the US biopharmaceutical industry from 1998–2002. We find an inverted U-shape relationship between the diversity of alliance partners’ industrial background and innovation performance, and a negative interaction of partner diversity and the diversity of the alliance objectives. This study contributes to the growing field of alliance portfolio diversity research by introducing a new alliance characteristic-based dimension of diversity and testing the interaction of different diversities. Our findings imply that firms with diverse alliance partners in particular need to be careful not to focus on too many objectives at the same time.

scholarly journals Biopharmaceutical Industry Capability Building in India: Report from a Symposium

2021 ◽  
Author(s):  
Annu Uppal ◽  
Ranjan Chakrabarti ◽  
Narendra Chirmule ◽  
Anurag Rathore ◽  
Fouad Atouf
Keyword(s):  
Control Strategies ◽  
Biopharmaceutical Industry ◽  
Gene Therapies ◽  
Governmental Agencies ◽  
Global Standards ◽  
Advanced Manufacturing Technologies ◽  
The Us ◽  
Capability Building ◽  
Manufacturing Technologies ◽  
And Control

AbstractThe biopharmaceutical industry is evolving with a shift in focus from recombinant proteins and antibodies towards more complex cell and gene therapies. To be competitive globally, biomanufacturers need to focus on aligning with global standards with regard to drug quality, reducing manufacturing failures and delivering drugs to market quickly. Building these capabilities requires a multifaceted approach that includes improvements in operations, quality compliance, and control strategies. To address these needs, the US Pharmacopeia (USP), the Department of Biotechnology (DBT) India, and the Confederation of Indian Industry (CII) held a symposium to discuss the requirements and gaps in the biotechnology and pharmaceutical sectors in India and other developing countries. A panel of experts from academia, manufacturing, and governmental agencies identified several drivers needed for capability building, including a skilled workforce, public–private partnerships, advanced manufacturing technologies, novel biologics, and favorable policies. This article summarizes the recommendations put forward by this panel.

The Eleventh Circuit Holds that Agreements in which Pharmaceutical Companies Pay Generic Companies Not to Compete May be Valid

2004 ◽  
Vol 32 (1) ◽  
pp. 181-184
Author(s):  
Amy Garrigues
Keyword(s):  
Pharmaceutical Companies ◽  
Court Decisions ◽  
Patent Holder ◽  
Trial Court ◽  
Court Of Appeals ◽  
The Us ◽  
Antitrust Laws ◽  
Per Se ◽  
Appeals Court ◽  
Two Sides

On September 15, 2003, the US. Court of Appeals for the Eleventh Circuit held that agreements between pharmaceutical and generic companies not to compete are not per se unlawful if these agreements do not expand the existing exclusionary right of a patent. The Valley DrugCo.v.Geneva Pharmaceuticals decision emphasizes that the nature of a patent gives the patent holder exclusive rights, and if an agreement merely confirms that exclusivity, then it is not per se unlawful. With this holding, the appeals court reversed the decision of the trial court, which held that agreements under which competitors are paid to stay out of the market are per se violations of the antitrust laws. An examination of the Valley Drugtrial and appeals court decisions sheds light on the two sides of an emerging legal debate concerning the validity of pay-not-to-compete agreements, and more broadly, on the appropriate balance between the seemingly competing interests of patent and antitrust laws.

Sign in / Sign up

Export Citation Format

Share Document